Newsroom
APIS Statement to Net Zero
APIS is committed to achieving Net Zero emissions by 2045 for emissions scopes 1, 2 and 3. The commitment was made on 25MAR24 by Ian Kavanagh, Chief Executive Officer.
25-March-2024
APIS Announces Publication on Breast Cancer Subtyping Kit by The Royal Surrey Hospital NHS Foundation Trust
The article is titled ‘Breast Cancer Molecular Subtyping in Practice: A Real-World Study of the APIS Breast Cancer Subtyping Assay in a Consecutive Series of Breast Core Biopsies‘ published in MDPI.
23-Feb-2024
APIS Releases First Publication on Breast Cancer Subtyping Kit
The article is titled ‘Comprehensive and Accurate Molecular Profiling of Breast Cancer through mRNA Expression of ESR1, PGR, ERBB2, MKI67, and a Novel Proliferation Signature‘ published in MDPI.
23-Jan-2024
APIS Announces New Collaboration
Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialise the APIS ESR1 Mutations Kit
12-Oct-2023
APIS Announces Changes to the Executive Management Team
APIS Assay Technologies Ltd. Announces Appointment of New CEO and Executive Chairman of the Board
20-Jul-2023
APIS Announces New Collaboration
PharmaKure and APIS Assay Technologies sign a collaboration for the development of Clickmers related to neurodegenerative diseases.
03-Jul-2023
APIS Announces New Partnership
Biocartis and APIS Assay Technologies Sign Collaboration to Develop and Commercialise a Breast Cancer Subtyping Test on the Idylla™
04-Apr-2023
APIS Assay Technologies Achieve ISO 13485:2016 Certification 2023
The design, development, manufacture and distribution of in vitro molecular diagnostics assays for detection of biomarkers linked to human diseases including cancer and infectious diseases.
02-Apr-2023
Clickmer Systems receives €1.1m grant to deliver innovative diagnostic platform for fast pandemic responsiveness
02-Feb-2023
‘Click’ Chemistry Wins Nobel Prize in Chemistry
07-Oct-2022
AI and Its Involvement in the Future of Neoantigen Discovery
22-Jan-2021
APIS Assay Technologies and Moffitt Cancer Center Sign Master Collaboration Agreement on TROLL Biomarker Assessment
11-Dec-2020
Pioneering research detects Hormone-Upregulated lncRNA within the lymphocyte-specific protein tyrosine kinase (HULLK) discovered in Prostate Cancer
13-Nov-2020
APIS Assay Technologies expands bioinformatics expertise with acquisition of Beogenomics
04-Sep-2020
APIS Assay Technologies Achieve ISO 13485:2016 Certification
02-Apr-2020
